In summary, a compound with the activity of an allosteric partial agonist of the TSH receptor has been created, which can become a prototype for pharmacological drugs for the correction of hypothyroidism, including that induced by T2DM and other metabolic and endocrine disorders. The gene discussed is TSHR; the disease is endocrine system disorder.